Acurx Pharmaceuticals (NASDAQ:ACXP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Acurx Pharmaceuticals (NASDAQ:ACXP) from a sell rating to a hold rating in a research report released on Saturday morning.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Acurx Pharmaceuticals in a research report on Tuesday, September 30th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Stock Down 4.8%

Acurx Pharmaceuticals stock opened at $4.14 on Friday. Acurx Pharmaceuticals has a 52-week low of $3.80 and a 52-week high of $28.00. The firm has a market capitalization of $8.65 million, a price-to-earnings ratio of -0.49 and a beta of -1.27. The firm has a 50-day moving average price of $5.28 and a two-hundred day moving average price of $6.61.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.23) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.38. Research analysts expect that Acurx Pharmaceuticals will post -0.89 earnings per share for the current year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. Armistice Capital LLC bought a new position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned approximately 70.13% of Acurx Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.